The move to targeted cancer therapies and individualized treatment makes it difficult to design studies that can clear regulatory hurdles. That can slow the development and delivery of promising new treatments. Investigational new drug (IND) application is already a difficult process of data and report gathering.

More and more oncology treatment researchers are looking for ways to smooth the IND path, no matter what the therapeutic is – cell-based, mAbs or small molecule. A new infographic presents a foundational roadmap to navigate a daunting IND application process. You’ll learn how the right partner can streamline and speed IND compliance, compressing go-to-market schedules. Discover how a right partner strategy can:

• Augment your team with experienced, knowledgeable advisors to help speed regulatory compliance
• Accelerate specialty filings such breakthrough therapy and fast-track designations
• Speed CMC decision-making on issues such as vendor selection and quality assurance

​​